The FINANCIAL -- GlaxoSmithKline plc announced that it has reached agreement to divest the majority of its “Classic Brands” in Australia to Aspen Global Incorporated for approximately £172 million in cash. 

The divested brands include Valtrex, Lamictal, Timentin, Amoxil and Aropax and generated total sales of approximately £83 million in 2011 and approximately £31 million in the first half of 2012.  Revenues for these products have gradually declined over recent years due to local market price reductions and generic competition. It is expected the divestment will complete in Q4 2012, subject to regulatory approvals. 

As GlaxoSmithKline reported, the net cash proceeds from the transaction are expected to be approximately £155 million. 

Net profit on this disposal in 2012 is estimated to be approximately £131 million, £121 million and will be recorded as a non-core item.   

As with the divestment of its non-core over-the-counter (OTC) brands earlier in 2012, today’s announcement is an example of GSK’s commitment to realise value and enhance returns to shareholders through the sale of low growth or non-core businesses and to focus on priority brands, products and pipeline opportunities that have long term growth potential. 

Related Stories

• Meeting in Russia brings together scientific experts from around the world
• Lilly Announces CEO Dr. John Lechleiter to Undergo Scheduled Surgery
• FDA Grants Premarket Approval (PMA) For The SEDASYS System For Healthy Patients